1型糖尿病的抗原特异性免疫疗法：发挥最大潜力。 - Suppr

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

作者信息

Peakman Mark, von Herrath Matthias

机构信息

Department of Immunobiology, National Institute for Health Research, Comprehensive Biomedical Research Centre at Guy's and St Thomas' National Health Service Foundation Trust, King's College London, London, UK.

出版信息

Diabetes. 2010 Sep;59(9):2087-93. doi: 10.2337/db10-0630.

DOI:10.2337/db10-0630

PMID:20805382

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2927927/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92ea/2927927/20fe494503b9/zdb0091062420001.jpg

相似文献

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.1型糖尿病的抗原特异性免疫疗法：发挥最大潜力。

Diabetes. 2010 Sep;59(9):2087-93. doi: 10.2337/db10-0630.

Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.多功能靶向树突状细胞的聚合物微粒：用于1型糖尿病的新型疫苗研发

Hum Vaccin. 2011 Jan 1;7(1):37-44. doi: 10.4161/hv.7.1.12916.

Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy.抗原特异性肽免疫疗法治疗 1 型糖尿病：安全性已证实，疗效有希望。

Cell Metab. 2017 Oct 3;26(4):595-597. doi: 10.1016/j.cmet.2017.09.016.

Immunotherapy-based strategies for the treatment of autoimmune diabetes: searching for the cure.基于免疫疗法的自身免疫性糖尿病治疗策略：寻找治愈方法。

Curr Pharm Des. 2011;17(29):3217-23. doi: 10.2174/138161211798157603.

Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes.用抗原特异性凋亡小体脉冲处理的树突状细胞可预防实验性 1 型糖尿病。

Clin Exp Immunol. 2010 May;160(2):207-14. doi: 10.1111/j.1365-2249.2009.04082.x. Epub 2009 Dec 17.

The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice.免疫调节性CD4+ T细胞的类型和频率决定了非肥胖糖尿病小鼠中抗原特异性免疫疗法的疗效。

Diabetes. 2007 May;56(5):1395-402. doi: 10.2337/db06-0543. Epub 2007 Feb 22.

Nasal tolerance induction as a potential means of immunotherapy for autoimmune diseases: implications for clinical medicine.诱导鼻耐受作为自身免疫性疾病免疫治疗的一种潜在手段：对临床医学的启示。

Clin Exp Allergy. 2000 Dec;30(12):1688-96. doi: 10.1046/j.1365-2222.2000.00972.x.

Biomarkers for antigen immunotherapy in allergy and type 1 diabetes.过敏和1型糖尿病中抗原免疫疗法的生物标志物。

Clin Immunol. 2015 Nov;161(1):44-50. doi: 10.1016/j.clim.2015.05.023. Epub 2015 Jun 27.

Antigen-specific therapeutic approaches in Type 1 diabetes.1 型糖尿病的抗原特异性治疗方法。

Cold Spring Harb Perspect Med. 2012 Feb;2(2):a007773. doi: 10.1101/cshperspect.a007773.

Immunomodulators: Cell savers.免疫调节剂：细胞回收器。

Nature. 2012 May 17;485(7398):S4-5. doi: 10.1038/485s4a.

引用本文的文献

Mechanism of Action of Oral -Based Vaccine to Prevent and Reverse Type 1 Diabetes in NOD Mice.口服疫苗预防和逆转非肥胖糖尿病（NOD）小鼠1型糖尿病的作用机制

Vaccines (Basel). 2024 Mar 6;12(3):276. doi: 10.3390/vaccines12030276.

Delivery route considerations for designing antigen-specific biomaterial strategies to combat autoimmunity.设计抗原特异性生物材料策略以对抗自身免疫时的给药途径考量

Adv Nanobiomed Res. 2023 Mar;3(3). doi: 10.1002/anbr.202200135. Epub 2023 Jan 29.

Preclinical Models to Evaluate the Human Response to Autoantigen and Antigen-Specific Immunotherapy in Human Type 1 Diabetes.评估人类 1 型糖尿病自身抗原和抗原特异性免疫治疗人体反应的临床前模型。

Front Endocrinol (Lausanne). 2022 Apr 13;13:883000. doi: 10.3389/fendo.2022.883000. eCollection 2022.

Enhancing Antigen Presentation and Inducing Antigen-Specific Immune Tolerance with Amphiphilic Peptides.两亲性肽增强抗原呈递和诱导抗原特异性免疫耐受。

J Immunol. 2021 Oct 15;207(8):2051-2059. doi: 10.4049/jimmunol.1901301. Epub 2021 Sep 15.

The dark side of insulin: A primary autoantigen and instrument of self-destruction in type 1 diabetes.胰岛素的阴暗面：1 型糖尿病的主要自身抗原和自我毁灭工具。

Mol Metab. 2021 Oct;52:101288. doi: 10.1016/j.molmet.2021.101288. Epub 2021 Jul 7.

Formation of pancreatic β-cells from precursor cells contributes to the reversal of established type 1 diabetes.前体细胞分化为胰腺β细胞有助于逆转已确立的 1 型糖尿病。

Cell Immunol. 2021 Jun;364:104360. doi: 10.1016/j.cellimm.2021.104360. Epub 2021 Apr 9.

Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses.免疫调节双粒径微粒系统将人类抗原呈递细胞诱导为耐受表型，并抑制 1 型糖尿病特异性自身反应性 T 细胞反应。

Front Immunol. 2020 Oct 22;11:574447. doi: 10.3389/fimmu.2020.574447. eCollection 2020.

Engineering immunomodulatory biomaterials for type 1 diabetes.用于1型糖尿病的工程免疫调节生物材料

Nat Rev Mater. 2019 Jun;4(6):429-450. doi: 10.1038/s41578-019-0112-5. Epub 2019 May 17.

Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route.1 型糖尿病的自身抗原治疗：选择自身抗原和给药途径的未解问题。

Int J Mol Sci. 2020 Feb 26;21(5):1598. doi: 10.3390/ijms21051598.

Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction.用 Tregitope-人血清白蛋白融合胰岛素肽进行治疗性给药，以促进抗原特异性适应性耐受诱导。

Sci Rep. 2019 Nov 6;9(1):16103. doi: 10.1038/s41598-019-52331-1.

本文引用的文献

Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.开发 1 型糖尿病联合免疫疗法：来自 ITN-JDRF 1 型糖尿病联合治疗评估小组的建议。

Clin Exp Immunol. 2010 May;160(2):176-84. doi: 10.1111/j.1365-2249.2010.04153.x.

The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse.1 型糖尿病生理实验室平台：一种经过验证的非肥胖型糖尿病小鼠发病机制的基于生理学的数学模型。

Clin Exp Immunol. 2010 Aug;161(2):250-67. doi: 10.1111/j.1365-2249.2010.04166.x. Epub 2010 May 18.

CD4+CD25+Foxp3+ T regulatory cells are not involved in oral desensitization.CD4+CD25+Foxp3+ T 调节细胞不参与口腔脱敏。

Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):359-61. doi: 10.1177/039463201002300136.

Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression.天然产生的能够识别胰岛自身抗原并分泌白细胞介素-10 的人 CD4 T 细胞通过连锁抑制来调节促炎 T 细胞反应。

Diabetes. 2010 Jun;59(6):1451-60. doi: 10.2337/db09-0503. Epub 2010 Mar 18.

Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells.用未成熟树突状细胞进行非肥胖型糖尿病小鼠的抗原依赖免疫治疗。

Clin Exp Immunol. 2010 Jun;160(3):331-9. doi: 10.1111/j.1365-2249.2010.04104.x. Epub 2010 Feb 18.

Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes.Foxp3+ T 细胞在肿瘤引流淋巴结中诱导依赖穿孔素的树突状细胞死亡。

Immunity. 2010 Feb 26;32(2):266-78. doi: 10.1016/j.immuni.2009.11.015. Epub 2010 Feb 4.

Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.免疫治疗试验设计中的替代终点：1 型糖尿病带来的新教训。

Nat Rev Immunol. 2010 Feb;10(2):145-52. doi: 10.1038/nri2705.

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.霉酚酸酯和达克珠单抗联合治疗新发 1 型糖尿病患者β细胞功能丧失。

Diabetes Care. 2010 Apr;33(4):826-32. doi: 10.2337/dc09-1349. Epub 2010 Jan 12.

Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes.用抗原特异性凋亡小体脉冲处理的树突状细胞可预防实验性 1 型糖尿病。

Clin Exp Immunol. 2010 May;160(2):207-14. doi: 10.1111/j.1365-2249.2009.04082.x. Epub 2009 Dec 17.

Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial.类风湿关节炎的表位特异性免疫疗法：在一项双盲、安慰剂对照的II期先导试验中，临床反应性伴随免疫偏离出现，且依赖于与T细胞耐受相关的一组分子的表达。

Arthritis Rheum. 2009 Nov;60(11):3207-16. doi: 10.1002/art.24916.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献